Pfizer/Warner-Lambert
This article was originally published in The Rose Sheet
Executive Summary
Divestiture of one overlapping consumer brand marketed in the U.S. required to receive Federal Trade Commission approval, Pfizer announces. Although the company declined to specifically name FTC's area of concern, it appears most likely Warner-Lambert's Nix and Pfizer's Rid pediculicides would need to be divested. One of the other few potential overlapping areas is mouthwash - W-L markets Listerine and Pfizer sells Plax. The agreement with FTC also involves the divestiture of one early clinical candidate for which the companies have overlapping research programs, Pfizer said. The closing is targeted for early to mid-June, according to Pfizer